Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. - Wikidata - wikimedia - TriplyDB

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.

http://www.wikidata.org/entity/Q44017442

about

Novel technologies and emerging biomarkers for personalized cancer immunotherapy Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate Regulation of tumor metastasis by myeloid-derived suppressor cells Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer Improving cancer immunotherapy by targeting the STATe of MDSCs Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis.Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.Clinical Development of Immune Checkpoint Inhibitors.Molecular pathways: myeloid complicity in cancer.Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy Evaluating biomarkers in melanoma.Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients.Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy.Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.The diverse roles of the TNF axis in cancer progression and metastasis.The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.Monitoring the immune competence of cancer patients to predict outcome.Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses.Therapeutic use of anti-CTLA-4 antibodies.T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

P2860

Q26770780-2CFB36AC-D90B-4EAA-B634-9C0A78A1DE19 Q26777205-B75BF6F5-CE42-48DF-8D9C-5F3C928DFB11 Q27022125-7133467D-AAE2-4C05-8559-0183EA3729AC Q28066486-2AC24EC2-DDA7-4534-B10B-50D3C41F7C49 Q28066797-CD9BB474-6FE6-48C8-81D2-73EEF220199B Q28075719-B428313A-2D1E-49B4-B17A-F5CD9894A39F Q28076161-B6F45728-7FDD-4176-9ADE-1068EF3DF3DB Q28076760-FCB75F59-2CFE-4FCE-975A-000B15798FBC Q28084627-0481F325-421C-4C83-B0AB-5AE75FADBE67 Q29994573-64D4A461-92B3-4C74-AE4C-BBB0870CF19B Q30578330-604E26CC-A384-48DC-9541-16108CEC0028 Q33564156-68622C2C-D6EA-4F2D-BFEF-AB6A62AFCA47 Q33587584-D596C76B-637E-40FE-B074-0358ACC15E55 Q33591598-C4CD0F83-C6AC-446B-A1FA-159CB1921C44 Q33641799-E1568DDC-A45E-430F-9E8C-10ADD72DF0C7 Q33913101-AA74F65C-531D-4EEE-A56E-5FB92925EB43 Q34016867-6C079C68-36B6-4E4E-91A5-34BD42D73CE4 Q34044797-551B7F53-341F-4D07-AFFB-4998BA5527B6 Q34412289-1E56E447-CF61-47DA-B7A6-EC31B78193F8 Q34671498-649BFA61-D4E0-4383-BEDE-706CDD0F0F17 Q34725969-6399B1C3-6FCB-4C9D-B9A6-5F55F9BB4B02 Q34810257-40F2F227-1AF3-426C-9D65-513BA5F584E1 Q35005677-17422991-DE4A-40B8-B9D1-DF6DA04D4228 Q35078852-EFD3AE67-77BC-4B35-9C36-5FE46EAE7E00 Q35225664-9AF64984-FBAC-419E-AAEE-3087706EA947 Q35507112-4B2A3E1F-B56A-4124-A01B-2D146D7001C6 Q36060268-EDA77522-EEC1-4F2B-AF87-D4B394ED5D6B Q36483105-ED3ECA14-13D1-4475-873E-D8863D118599 Q36503123-84DEA07A-7415-47DE-986F-BA4AB5C963AA Q36711007-E796BB7E-DCD2-4085-A2B8-A1E227DB07FE Q36759111-C66A8C3F-31A8-498B-8CD7-36887DDA4D0D Q36821143-D70C52EB-E3E0-48F7-BFC1-9F0299F5C1D3 Q37447879-FA94A3EA-78B6-4B58-B649-309519265EEA Q37474735-36900423-E46E-43C1-9B20-700FB23D015D Q37729321-464EB64D-E4B2-4380-938F-A255F16E736E Q38184391-C2CFF34F-7255-49A6-A74E-21713B0623A4 Q38207587-157FE642-C242-4E1C-95A6-8574B555451E Q38231154-97D23561-261D-4B38-81C4-E1466F660EC8 Q38344066-082636B5-CC62-483D-9BE9-3867BEC05643 Q38413904-6EDBB956-062D-49E3-B835-E73D769A0A28

P2860

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.

http://www.wikidata.org/entity/Q44017442

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Frequencies of circulating MDS ...... ients treated with ipilimumab.

@en

Frequencies of circulating MDS ...... ients treated with ipilimumab.

@nl

type

label

Frequencies of circulating MDS ...... ients treated with ipilimumab.

@en

Frequencies of circulating MDS ...... ients treated with ipilimumab.

@nl

prefLabel

Frequencies of circulating MDS ...... ients treated with ipilimumab.

@en

Frequencies of circulating MDS ...... ients treated with ipilimumab.

@nl

P1433

Q44017442-977CAB80-934E-46FF-A311-03D91817993D

P1476

Q44017442-C76CED62-02CC-4C54-8D60-FAB3F9A1AD37

P2093

Q44017442-017203CA-764A-4BD1-86CF-524F88D50F4D

Q44017442-1727E99D-C298-4A4F-9E30-C8724CBA33FA

Q44017442-194354FB-6B95-4AF2-B649-0A43570B02AE

Q44017442-25B568CD-12E4-4639-B442-A691CC40B952

Q44017442-2AB122BB-32D6-4584-BBDC-92DE9770FB76

Q44017442-4279ED03-82DA-4E47-811F-F0D8992E6486

Q44017442-7183A028-B152-4DD1-BE7E-9E12D124732F

Q44017442-D306F7F0-3BE4-41F2-BA4C-64B1CAD2E1CD

Q44017442-D99F53E6-5172-43B0-B519-27D938C43BC4

P2860

Q44017442-000533AC-0E7D-42D7-B5BB-EB92964011CD

Q44017442-072B2AB0-2430-4F97-AD66-FB35F58B0419

Q44017442-08A6E26A-9A92-4A41-B22E-EE855C1BD585

Q44017442-0C1C4CFD-BB76-4871-AE8E-3DA2A9AD4EB7

Q44017442-0C583BFC-850E-46D4-8C23-44208C27D21E

Q44017442-0F308919-BBF9-4CA8-B8DA-8CEBF5588D86

Q44017442-0FAB69FA-5BD8-4838-BAC6-3D1FB36B506E

Q44017442-124F5F1D-A417-4DC8-8DA0-90925DE5DE5F

Q44017442-185F0A10-A52A-4310-8190-8C6C83688864

Q44017442-1925DF3D-876C-4C0A-88C4-74A025D2E82F

P2888

Q44017442-BE9CCC66-DC15-4E99-9BC3-3193EC66EB6B

P304

Q44017442-24A3CAD7-E4A9-42E4-B5F2-8A51296DC65A

P31

Q44017442-CE00615E-0B3A-42D2-BA44-FEA2CEA39233

P356

Q44017442-294BCE29-E7B5-4873-8F14-153065CF265C

P433

Q44017442-82E7009A-F840-4FD2-A1A4-CF3E9620A538

P478

Q44017442-DCBD89D5-7849-4972-AB41-329AAD9AD7C6

P577

Q44017442-F1160DA3-9748-4130-A727-C53A5185F6B2

P698

Q44017442-6A995AB0-D14E-4F6A-8EB0-F9109F01264C

P921

Q44017442-37B44D9E-1C41-4178-8E32-A71D2A29D513

P356

S00262-013-1508-5

P1433

Cancer Immunology, Immunotherapy

P1476

Frequencies of circulating MDS ...... ients treated with ipilimumab.

@en

P2093

Carla M Costa-Nunes

http://www.w3.org/2001/XMLSchema#string

Christiane Meyer

http://www.w3.org/2001/XMLSchema#string

Daniel E Speiser

http://www.w3.org/2001/XMLSchema#string

Emanuela Romano

http://www.w3.org/2001/XMLSchema#string

Laurène Cagnon

http://www.w3.org/2001/XMLSchema#string

Loredana Leyvraz

http://www.w3.org/2001/XMLSchema#string

Nicole Montandon

http://www.w3.org/2001/XMLSchema#string

Olivier Michielin

http://www.w3.org/2001/XMLSchema#string

Petra Baumgaertner

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Myeloid-derived suppressor cells: linking inflammation and cancer

The blockade of immune checkpoints in cancer immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Coordinated regulation of myeloid cells by tumours

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

P2888

s00262-013-1508-5

P304

247-257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-013-1508-5

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24357148

http://www.w3.org/2001/XMLSchema#string

P921